|
|
| | NDRG1 antibody Chemical Properties |
| | NDRG1 antibody Usage And Synthesis |
| Source | Rabbit | | Applications | The antibody has been tested by ELISA, Western blot analysis, Flow cytometry and ICC/IF to assure specificity and reactivity. | | Reactivity | Human;Mouse;Rat;Monkey | | Immunogen | Anti-human NDRG1 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human NDRG1 protein 1-394 amino acids purified from E. coli.
| | Background | NDRG1 is a cytoplasmic protein that is involved in stress responses, hormone responses, cell growth, and differentiation. NDRG1 is one of 4 members of the NDRG ?/?-hydrolase family. NDRG1 is classified in databases as a tumor suppressor and heavy metal-response protein. NDRG1’s functions include cell-cycle regulation, cellular differentiation, apoptosis, hypoxia response and metal-ion sensing. NDRG1 is also essential for p53-mediated caspase activation and apoptosis. The NDRG1 is a Rab4a effector that is involved in vesicular recycling of E-cadherin. NDRG1 is ubiquitous; it is expressed most notably in placental membranes and prostate, kidney, small intestine, and ovary tissues. NDRG1 has reduced expression in adenocarcinomas compared to normal tissues.
NDRG1 gene mutations are reported to be the cause for hereditary motor and sensory neuropathy-Lom (HMSNL), which is a severe autosomal recessive form of Charcot- Marie-Tooth (CMT) disease. In addition, decreased NDRG1 expression in glioma is linked to tumor progression. On the other hand, overexpression of NDRG1 is connected to malignant status of esophageal cancer. NDRG1 may also have a role in portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. | | References | [1] Shimono, A. et al. (1999) Mech Dev 83, 39-52.
[2] Zhou, D. et al. (1998) Cancer Res 58, 2182-9.
[3] van Belzen, N. et al. (1997) Lab Invest 77, 85-92.
[4] Kurdistani, S.K. et al. (1998) Cancer Res 58, 4439-44.
[5] Park, H. et al. (2000) Biochem Biophys Res Commun 276, 321-8.
[6] Li, J. and Kretzner, L. (2003) Mol Cell Biochem 250, 91-105.
[7] Stein, S. et al. (2004) J Biol Chem 279, 48930-40.
[8] Maruyama, Y. et al. (2006) Cancer Res 66, 6233-42.
[9] Nishio, S. et al. (2008) Cancer Lett 264, 36-43.
[10] Kalaydjieva, L. et al. (2000) Am J Hum Genet 67, 47-58.
|
| | NDRG1 antibody Preparation Products And Raw materials |
|